Patents by Inventor Michael Benjamin Battles

Michael Benjamin Battles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cross-reactive antibody
    Patent number: 9914767
    Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: March 13, 2018
    Assignee: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Lukas Stulik, Gábor Nagy, Irina Mirkina, Zoltán Magyarics, Zehra Visram, Michaela Jaegerhofer, Manuel Zerbs, Ivana Dolezilkova, Astrid Teubenbacher, Michael Benjamin Battles, Bianka Dominique Prinz
  • ANTIBODIES DIRECTED AGAINST THE LukGH (LukAB) TOXIN OF STAPHYLOCOCCUS AUREUS AND ANTIBODY SEQUENCES
    Publication number: 20160340415
    Abstract: The invention provides for an antibody comprising at least one binding site that specifically binds to a LukGH complex, which antibody comprises at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in Table 1, or functionally active CDR variants thereof.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 24, 2016
    Inventors: Eszter NAGY, Adriana BADARAU, Harald ROUHA, Irina MIRKINA, Michael Benjamin BATTLES, Laura M. WALKER, Nels NIELSON, S. Jain TUSHAR
  • CROSS-REACTIVE STAPHYLOCOCCUS AUREUS ANTIBODY SEQUENCES
    Publication number: 20160244511
    Abstract: The invention refers to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, which antibody comprises at least three complementarity determining regions (CDR1 to CDR3) of the antibody heavy chain variable region (VH), wherein A) the antibody comprises a) a CDR1 comprising or consisting of the amino acid sequence YSISSGMGWG (SEQ ID 1); and b) a CDR2 comprising or consisting of the amino acid sequence SIDQRGSTYYNPSLKS (SEQ ID 2); and c) a CDR3 comprising or consisting of the amino acid sequence ARDAGHGVDMDV (SEQ ID 3); or B) the antibody comprises at least one functionally active CDR variant of a) the parent CDR1 consisting of the amino acid sequence of SEQ ID 1; or b) the parent CDR2 consisting of the amino acid sequence of SEQ ID 2; or c) the parent CDR3 consisting of the amino acid sequence of SEQ ID 3; wherein the functionally active CDR variant comprises at least one point mutati
    Type: Application
    Filed: October 17, 2014
    Publication date: August 25, 2016
    Inventors: Eszter NAGY, Adriana BADARAU, Harald ROUHA, Gabor NAGY, Irina MIRKINA, Zoltan MAGYARICS, Zebra VISRAM, Michael Benjamin BATTLES, Bianka Dominique PRINZ, Tushar S. JAIN
  • GENERATION OF HIGHLY POTENT ANTIBODIES NEUTRALIZING THE LUKGH (LUKAB) TOXIN OF STAPHYLOCOCCUS AUREUS
    Publication number: 20160108106
    Abstract: The subject relates to an isolated Staphylococcus aureus leukocidin antigen comprising a LukGH complex, an antibody specifically binding to the Luk GH complex, and the human CD11b/CD18 complex for use in a method of determining the binding or toxicity of the Staphylococcus aureus Luk GH bi-component cytolysin.
    Type: Application
    Filed: May 16, 2014
    Publication date: April 21, 2016
    Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Zoltán Magyarics, Sophia Zettl, Michael Benjamin Battles
  • CROSS-REACTIVE STAPHYLOCOCCUS AUREUS ANTIBODY
    Publication number: 20150086539
    Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 26, 2015
    Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Lukas Stulik, Gábor Nagy, Irina Mirkina, Zoltán Magyarics, Zehra Visram, Michaela Jaegerhofer, Manuel Zerbs, Ivana Dolezilkova, Astrid Teubenbacher, Michael Benjamin Battles, Bianka Dominique Prinz